{"id":"atezolizumab-and-talazoparib","_chembl":{"chemblId":"CHEMBL3707227","moleculeType":"Antibody"},"allNames":"atezolizumab and talazoparib","_dailymed":null,"mechanism":{"target":"PD-L1, PARP","drugClass":"PD-L1 inhibitor, PARP inhibitor","explanation":"Atezolizumab works by binding to PD-L1, a protein that can suppress the immune system, thereby enhancing the body's immune response against cancer cells. Talazoparib, on the other hand, blocks PARP enzymes, which are crucial for repairing damaged DNA in cancer cells, leading to their death.","oneSentence":"Atezolizumab binds to PD-L1, blocking its interaction with PD-1 and B7.1, enhancing T-cell activation, while Talazoparib inhibits PARP enzymes, leading to DNA damage accumulation and cancer cell death."},"_scrapedAt":"2026-03-28T01:47:42.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:45:56.049516+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04334941","phase":"PHASE2","title":"Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-20","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":103},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT04486352","phase":"PHASE1, PHASE2","title":"A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-10-20","conditions":"Endometrial Cancer","enrollment":148},{"nctId":"NCT06762808","phase":"PHASE2","title":"Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-05-01","conditions":"Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT04690855","phase":"PHASE2","title":"A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Mylin A. Torres, MD","startDate":"2021-10-04","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":1},{"nctId":"NCT04591431","phase":"PHASE2","title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","status":"UNKNOWN","sponsor":"Fondazione per la Medicina Personalizzata","startDate":"2020-10-07","conditions":"Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT04801966","phase":"NA","title":"Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study","status":"TERMINATED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-09-23","conditions":"Cancer","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Atezolizumab and Talazoparib","genericName":"atezolizumab-and-talazoparib","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":8,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:45:56.049516+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}